These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21076451)

  • 1. Increased fetuin-A levels following treatment with a vitamin D analog.
    Manenti L; Vaglio A; Pasquali S
    Kidney Int; 2010 Dec; 78(11):1187; author reply 1187-9. PubMed ID: 21076451
    [No Abstract]   [Full Text] [Related]  

  • 2. Cinacalcet, fetuin-A and interleukin-6.
    Marino A; Giotta N
    Nephrol Dial Transplant; 2008 Apr; 23(4):1460-1; author reply 1461-2. PubMed ID: 18065786
    [No Abstract]   [Full Text] [Related]  

  • 3. What is it for?
    Braun J
    Nephrol Dial Transplant; 2012 Oct; 27(10):3965-6; author reply 3966-7. PubMed ID: 23114909
    [No Abstract]   [Full Text] [Related]  

  • 4. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What does the circulating AHSG/fetuin-A level tell us?
    Kazama JJ
    Clin Exp Nephrol; 2007 Dec; 11(4):336-337. PubMed ID: 18085398
    [No Abstract]   [Full Text] [Related]  

  • 6. Fetuin-mineral complex reflects extraosseous calcification stress in CKD.
    Hamano T; Matsui I; Mikami S; Tomida K; Fujii N; Imai E; Rakugi H; Isaka Y
    J Am Soc Nephrol; 2010 Nov; 21(11):1998-2007. PubMed ID: 20947626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paricalcitol in secondary hyperparathyroidism and the survival benefit in patients with chronic kidney disease.
    Al-Baaj F; Yadav P; Al-Rifai A
    J Ren Care; 2011 Jun; 37(2):75-9. PubMed ID: 21561542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hectorol: a new vitamin D prohormone.
    St Peter WL
    Nephrol Nurs J; 2000 Feb; 27(1):67-8. PubMed ID: 10852695
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.
    Hervás Sánchez JG; Prados Garrido MD; Polo Moyano A; Cerezo Morales S
    Nefrologia; 2011; 31(6):697-706. PubMed ID: 22130286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised clinical study of alfacalcidol and paricalcitol.
    Hansen D
    Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival differences between activated injectable vitamin D2 and D3 analogs.
    Kalantar-Zadeh K
    Kidney Int; 2007 Apr; 71(8):827; author reply 827-8. PubMed ID: 17429422
    [No Abstract]   [Full Text] [Related]  

  • 14. Development and validation of an immunoluminometric assay (ILMA) for fetuin-A-glycoprotein.
    Bäumer A; Schmidt-Gayk H; Aulmann M; Kim TS
    J Immunoassay Immunochem; 2010; 31(1):10-23. PubMed ID: 20391014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microalbuminuria, another use for paricalcitol? Our experience in advanced chronic kidney disease.
    Blanco-García R; Bravo-López JJ; Moreiras-Plaza M; Nájera-de la Garza W; Cossio-Annibar C; Beato-Coo L; Rodríguez-Goyanes G
    Nefrologia; 2012 May; 32(3):401-2. PubMed ID: 22592429
    [No Abstract]   [Full Text] [Related]  

  • 16. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
    Fishbane S; Shapiro WB; Corry DB; Vicks SL; Roppolo M; Rappaport K; Ling X; Goodman WG; Turner S; Charytan C
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease.
    Monier-Faugere MC; Mawad H; Malluche HH
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1255-60. PubMed ID: 17942766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paricalcitol for pre-dialysis stages of chronic kidney disease.
    Almirall J; Bolos MI
    Nefrologia; 2012; 32(2):250-1; author reply 251-2. PubMed ID: 22466270
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges.
    Komaba H; Shiizaki K; Fukagawa M
    Expert Opin Biol Ther; 2010 Dec; 10(12):1729-42. PubMed ID: 21058933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol.
    Hernandez JD; Wesseling K; Boechat MI; Gales B; Salusky IB
    Nat Clin Pract Nephrol; 2007 Apr; 3(4):227-32. PubMed ID: 17389892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.